Minerva Neurosciences Inc(NERV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:23 PM ET (Korea 10/31 06:23)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -28.87 | Insider Own | 21.08% | Shs Outstand | 47.2M | Perf Week | 0.87% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | 73.02% | Insider Trans | - | Shs Float | 37.7M | Perf Month | -28.17% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | -0.17 | Inst Own | 76.08% | Short Float | 6.39% | Perf Quarter | -41.56% |
| Income | -0.40B | P/S | - | EPS this Y | -33.33% | Inst Trans | 6.53% | Short Ratio | 13.3 | Perf Half Y | -61.78% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 36.24% | ROA | -628.4% | Short Interest | 2.41M | Perf YTD | -42.29% |
| Book/sh | -4.52 | P/C | 1.47 | EPS past 3/5Y | -79.32% - | ROE | - | 52W High | -73.64% ($8.80) | Perf Year | -42.57% |
| Cash/sh | 1.58 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 9.43% ($2.12) | Perf 3Y | -42.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -2012.66% | Gross Margin | - | Volatility(W/M) | 10.1% 9.98% | Perf 5Y | -79.29% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.25 | Perf 10Y | -97.39% |
| Dividend Ex-Date | - | Quick Ratio | 20.14 | EPS Q/Q | 67.97% | Profit Margin | - | RSI (14) | 32.45 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 20.14 | Sales Q/Q | - | SMA20 | -10.91% ($2.6) | Beta | 0.01 | Target Price | $10.33 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/7 | SMA50 | -33.51% ($3.49) | Rel Volume | 2.18 | Prev Close | $2.24 |
| Employees | 7 | LT Debt/Eq | - | EPS/Sales Surpr. | 27.57% - | SMA200 | -52.65% ($4.9) | Avg Volume(3M) | 0.18M | Price | $2.32 |
| IPO | 2014/7/1 | Option/Short | Yes/Yes | Trades | 1840 | Volume | 394,698 | Change | 3.57% |
🧠 Minerva Neurosciences (NERV) is a clinical-stage biotech company developing treatments for central nervous system disorders. Its lead candidate, roluperidone, targets the unmet need of negative symptoms in schizophrenia, and it embodies the classic drug-development structure in which clinical results and regulatory progress drive the company's value.
Over the past 1 year, on the lower side
74% below its 1-year high.
Traded more than usual. That is 218% of its average volume.
NERV has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -33.3% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -79.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 76.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #344 of 597 in the industry
Based on market cap of $111M.
NKTX#343 Nkarta Inc $112M PER - NERV#344 Minerva Neurosciences Inc $111M PER - 
AVXL#345 Anavex Life Sciences Corp $110M PER - 
PYPD#346 Polypid Ltd $109M PER - 
ANIX#347 Anixa Biosciences Inc $108M PER - 
FAQ
What kind of company is NERV?
NERV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NERV?
The market cap of NERV is approximately $111M, ranking 4,398 within its sector.
What is the 52-week high and low for NERV?
NERV has recorded a 52-week high of $8.80 and a low of $2.12.
